000112466 001__ 112466
000112466 005__ 20240319080958.0
000112466 0247_ $$2doi$$a10.3390/vaccines10050781
000112466 0248_ $$2sideral$$a128534
000112466 037__ $$aART-2022-128534
000112466 041__ $$aeng
000112466 100__ $$aIguacel, I.
000112466 245__ $$aCitizen stance towards mandatory COVID-19 vaccination and vaccine booster doses: a study in Colombia, El Salvador and Spain
000112466 260__ $$c2022
000112466 5060_ $$aAccess copy available to the general public$$fUnrestricted
000112466 5203_ $$aThe infections and deaths resulting from Coronavirus Disease 2019 (COVID-19) triggered the need for some governments to make COVID-19 vaccines mandatory. The present study aims to analyze the position of 3026 adults in Colombia, El Salvador, and Spain regarding the possibility of making COVID-19 vaccine mandatory and the intention to be vaccinated with the booster or possible successive doses. Data from an online survey conducted from August to December 2021 among a non-representative sample of Spanish-speaking countries were collected. Multinomial Logistic Regression Models were used. A total of 77.4% of Colombians were in favor of mandatory vaccination compared to 71.5% of Salvadorians and 65.4% of Spaniards (p < 0.000). Women and people over 65 years of age were the groups most in favor of making the vaccine mandatory (p < 0.000). A total of 79.4% said they had received a third dose or would intend to receive the third dose or future doses, if necessary, compared with 9.4% who expressed doubts and 9.9% who refused to be vaccinated or did not intend to be vaccinated. Among the measures that could be taken to motivate vaccination, 63.0% and 60.6% were in favor of requiring a negative test to enter any place of leisure or work, respectively, compared to 16.2% in favor of suspension from work without pay. The acceptance of mandatory vaccination and of third or future doses varies greatly according to sociodemographic characteristics and work environment. As such, it is recommended that policy makers adapt public health strategies accordingly.
000112466 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000112466 590__ $$a7.8$$b2022
000112466 592__ $$a1.655$$b2022
000112466 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b24 / 136 = 0.176$$c2022$$dQ1$$eT1
000112466 593__ $$aDrug Discovery$$c2022$$dQ1
000112466 591__ $$aIMMUNOLOGY$$b32 / 161 = 0.199$$c2022$$dQ1$$eT1
000112466 593__ $$aImmunology$$c2022$$dQ1
000112466 593__ $$aPharmacology (medical)$$c2022$$dQ1
000112466 593__ $$aPharmacology$$c2022$$dQ1
000112466 593__ $$aInfectious Diseases$$c2022$$dQ1
000112466 594__ $$a7.0$$b2022
000112466 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000112466 700__ $$aÁlvarez-Najar, J. P.
000112466 700__ $$aVásquez, P. C.
000112466 700__ $$aAlarcón, J.
000112466 700__ $$aOrte, M. Á.
000112466 700__ $$aSamatán, E.
000112466 700__ $$aMartínez Jarreta, B.
000112466 773__ $$g10, 5 (2022), 781 [12 pp.]$$tVaccines$$x2076-393X
000112466 8564_ $$s283714$$uhttps://zaguan.unizar.es/record/112466/files/texto_completo.pdf$$yVersión publicada
000112466 8564_ $$s2653440$$uhttps://zaguan.unizar.es/record/112466/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000112466 909CO $$ooai:zaguan.unizar.es:112466$$particulos$$pdriver
000112466 951__ $$a2024-03-18-13:50:18
000112466 980__ $$aARTICLE